Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilofotase Alfa in Patients at Risk for Renal Damage Following Open Heart Surgery
NCT06168799Phase 2Completed
- Sponsor
- AM-Pharma
- Start
- Dec 2023
- Primary completion
- Oct 2025
- Modality
- Replacement Enzymes
- Countries
- 5
01
Overview
A Phase 2 trial of ilofotase alfa in acute kidney injury (AKI), sponsored by AM-Pharma. Started Dec 2023; status: completed.
02
Drugs
ilofotase alfa
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT06168799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06168799.